↓ Skip to main content

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes

Overview of attention for article published in Diabetes Therapy, July 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#6 of 478)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

twitter
102 tweeters

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
47 Mendeley
Title
Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
Published in
Diabetes Therapy, July 2017
DOI 10.1007/s13300-017-0277-0
Pubmed ID
Authors

Fernando Gomez-Peralta, Cristina Abreu, Albert Lecube, Diego Bellido, Alfonso Soto, Cristóbal Morales, Miguel Brito-Sanfiel, Guillermo Umpierrez

Abstract

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for the treatment of type 2 diabetes. They block the reabsorption of filtered glucose in kidneys, mainly in proximal renal tubules, resulting in increased urinary glucose excretion and correction of the diabetes-related hyperglycemia. Beyond improving glucose control, SGLT2 inhibitors offer potential benefits by reducing body weight and blood pressure. On the basis of the efficacy demonstrated in clinical trials, SGLT2 inhibitors are recommended as second- or third-line agents for the management of patients with type 2 diabetes. Beneficial effects on kidney disease progression, cardiovascular and all-cause mortality, and hospitalization for heart failure have also been demonstrated with one SGLT2 inhibitor (empagliflozin). Potential adverse events resulting from their mechanism of action or related to concomitant therapies are reviewed. A treatment algorithm for the adjustment of concomitant therapies after initiating SGLT2 inhibitors is also proposed.

Twitter Demographics

The data shown below were collected from the profiles of 102 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 47 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 7 15%
Unspecified 6 13%
Researcher 6 13%
Other 6 13%
Student > Master 6 13%
Other 16 34%
Readers by discipline Count As %
Medicine and Dentistry 20 43%
Unspecified 11 23%
Pharmacology, Toxicology and Pharmaceutical Science 6 13%
Nursing and Health Professions 3 6%
Biochemistry, Genetics and Molecular Biology 2 4%
Other 5 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 63. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2018.
All research outputs
#274,128
of 13,516,340 outputs
Outputs from Diabetes Therapy
#6
of 478 outputs
Outputs of similar age
#11,479
of 265,319 outputs
Outputs of similar age from Diabetes Therapy
#1
of 21 outputs
Altmetric has tracked 13,516,340 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 478 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,319 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.